Ronald E. Blaylock
Ronald E. Blaylock's purchase track record
Ronald E. Blaylock has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/5/2026 | PFE | $999K | pending | pending | — |
| 2/13/2025 | PFE | $499K | -10.2% | +1.5% | +5.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
W.R. Berkley Eyes Earnings Beat in Q3. W.R. Berkley is expected to post a Q3 earnings beat, with analysts highlighting key metrics such as reserve gains and investment income. The company’s performance is being closely watched as part of the broader insurance earnings season. Investors are noting the firm’s solid fundamentals, including a trailing P/E of 14.3 and a dividend yield of 0.54%.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
CarMax Reports Earnings Turnaround Progress Amid Margin Pressure. CarMax reported earnings that show progress in its turnaround, with sales surging due to cost-cutting measures. However, the company faces ongoing margin pressure, which remains a challenge despite the positive revenue trends. Analysts have recently increased the consensus price target to $61.37, reflecting a mix of optimism about the cost savings and caution regarding profitability.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Advantage Solutions Reports Q2 2026 Earnings. Advantage Solutions held its Q2 2026 earnings conference call, sharing results and guidance. The call was broadcast on Benzinga. The company discussed its financial performance and future plans. The session follows the stock trading near a key support level and a moderate RSI.
Transaction History
| PFE | ▲ Buy | Open Market | 39,231 | $999K | 8/5/2026 | View on chart |
| WRB | ▲ Buy | Grant | 3,090 | $0 | 6/3/2026 | View on chart |
| WRB | ▲ Buy | Grant | 2,776 | $0 | 6/11/2025 | View on chart |
| PFE | ▲ Buy | Open Market | 19,457 | $499K | 2/13/2025 | View on chart |
| KMX | ▲ Buy | Grant | 2,598 | $0 | 7/1/2024 | View on chart |
| WRB | ▲ Buy | Grant | 2,534 | $0 | 6/12/2024 | View on chart |
| KMX | ▲ Buy | Grant | 2,210 | $0 | 6/30/2023 | View on chart |
| WRB | ▲ Buy | Grant | 3,479 | $0 | 6/14/2023 | View on chart |
| KMX | ▲ Buy | Grant | 1,996 | $0 | 7/1/2022 | View on chart |
| WRB | ▲ Buy | Grant | 2,995 | $0 | 6/15/2022 | View on chart |
| ADV | ▲ Buy | Grant | 40,603 | $0 | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff
Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.